GlassScriptPhysician profile
Sharon Lee
NPI 1043958036
$963.55
in general payments reported to CMS, 2019-2025
18 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $93.73 · 2024: $342 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $192.41 | 2023-2025 | Taltz, Zepbound, Mounjaro |
| Janssen Biotech, INC. | $177.53 | 2024-2025 | Tremfya |
| Alexion Pharmaceuticals, INC. | $140.24 | 2023-2025 | Strensiq |
| Almatica Pharma LLC | $65.27 | 2024-2025 | Teriparatide |
| Ucb, INC. | $62.88 | 2023-2025 | Cimzia, Bimzelx |
| Organon LLC | $61.38 | 2024-2025 | Renflexis, Hadlima |
| Novo Nordisk INC | $36.72 | 2024-2025 | Ozempic, Rybelsus |
| Amgen INC. | $36.41 | 2024-2025 | Krystexxa, Evenity |
| Mallinckrodt Hospital Products INC. | $29.81 | 2025 | Acthar |
| Kyowa Kirin, INC. | $22.13 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $20.83 | 2024 | Saphnelo |
| Radius Health, INC. | $19.64 | 2025 | Tymlos |
| Dexcom, INC. | $19.46 | 2024 | Dexcom G6 Transmitter |
| Rgh Enterprises LLC | $18.18 | 2025 | |
| Fresenius Kabi USA, LLC | $15.91 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $15.83 | 2025 | Minimed 780g |
| Inspire Medical Systems, INC. | $14.65 | 2025 | Inspire |
| Abbott Laboratories | $14.27 | 2024 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.